When will Niraparib be available in China?

In December 2019, niraparib was approved for marketing in China through the relevant regulations of the National Medical Products Administration. It is the first domestic innovative drug for ovarian cancer and the first Class 1 new drug PARP inhibitor. The generic drug name of niraparib is niraparib tosylate capsules, and its trade name is Zele. It has also been included in the Category B drug catalog. Niraparib is an inhibitor of PARP enzymes (including PARP-1 and PARP-2) and plays a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve the inhibition of PARP enzyme activity and the increase in PARP-DNA complex formation, leading to DNA damage, apoptosis, and cell death.